{"id":"tamsulosin","brandName":"Flomax","genericName":"tamsulosin","companyId":"boehringer-ingelheim","companyName":"Boehringer Ingelheim","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, Alpha-1A adrenergic receptor"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1456 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1367 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"1202 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1159 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"999 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"977 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"908 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"870 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"864 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"825 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Dizziness","drugRate":"16%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"9.1%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"8.3%","severity":"common","organSystem":""},{"effect":"Infection","drugRate":"7.3%","severity":"common","organSystem":""},{"effect":"Back Pain","drugRate":"6.3%","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"5.1%","severity":"common","organSystem":""},{"effect":"Chest Pain","drugRate":"4.1%","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"2.3%","severity":"common","organSystem":""}],"contraindications":["Breastfeeding (mother)","Cataract surgery","Disease of liver","Dizziness","High-Grade Prostate Cancer","Intraoperative floppy iris syndrome","Oligozoospermia","Orthostatic hypotension","Pregnancy, function","Priapism","Syncope"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Syncope","drugRate":"0.4%","severity":"serious"},{"effect":"Symptomatic Postural Hypotension","drugRate":"0.4%","severity":"serious"},{"effect":"Vertigo","drugRate":"1%","severity":"serious"}]},"trials":["NCT06677177","NCT03229889","NCT02958878","NCT06257576","NCT03246880","NCT01533597","NCT05759767","NCT01534351","NCT06001619","NCT04987892","NCT01076309","NCT05494567","NCT02034604","NCT02247505","NCT05977647","NCT02184585","NCT04232683","NCT01175382","NCT02169713","NCT06282731","NCT02244294","NCT07444385","NCT05570084","NCT06264414","NCT02483793","NCT07134907","NCT02869971","NCT01254071","NCT07447518","NCT02417831","NCT01741454","NCT02573311","NCT04434378","NCT02827578","NCT00831701","NCT07156916","NCT02645890","NCT02972268","NCT02038868","NCT06262048","NCT01149746","NCT04807569","NCT00771394","NCT00448123","NCT05753670","NCT06491108","NCT00540124","NCT02417844","NCT01937871","NCT01777269"],"indications":{"approved":[{"name":"Benign prostatic hyperplasia","diseaseId":"benign-prostatic-hyperplasia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT06677177","phase":"NA","title":"The Efficacy of Nano-water in Combination With Tamsulosin-Dutasteride for Alleviating Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"ALI KAMAL M. SAMI","isPivotal":false,"enrollment":210,"indication":"Lower Urinary Tract Symptoms","completionDate":"2022-11-19"},{"nctId":"NCT03229889","phase":"Phase 4","title":"Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy and Endoscopic-Guided Percutaneous Nephrolithotomy: A Randomized Double-Blind Placebo Controlled Trial of Tadalafil, Tamsul","status":"COMPLETED","sponsor":"University of California, Irvine","isPivotal":false,"enrollment":220,"indication":"Nephrolithiasis","completionDate":"2022-03-24"},{"nctId":"NCT02958878","phase":"Phase 4","title":"Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair","status":"COMPLETED","sponsor":"Ascension Health","isPivotal":false,"enrollment":210,"indication":"Postoperative Urinary Retention","completionDate":"2018-11-30"},{"nctId":"NCT06257576","phase":"Phase 3","title":"Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter: a Randomized Clinical Trial","status":"RECRUITING","sponsor":"Emory University","isPivotal":true,"enrollment":212,"indication":"Postoperative Urinary Tract Infection","completionDate":"2026-02"},{"nctId":"NCT03246880","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","isPivotal":true,"enrollment":455,"indication":"Benign Prostatic Hyperplasia","completionDate":"2016-05"},{"nctId":"NCT01533597","phase":"Phase 4","title":"Comparison of the Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With OAB: A Prospective Randomized Multicenter Study","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","isPivotal":false,"enrollment":70,"indication":"Overactive Bladder","completionDate":"2014-02"},{"nctId":"NCT05759767","phase":"NA","title":"The Efficacy and Safety of Medical Expulsive Therapy After Extracorporeal Shock Wave Lithotripsy (ESWL) in Pediatric Urolithiasis","status":"UNKNOWN","sponsor":"Mansoura University","isPivotal":false,"enrollment":120,"indication":"Tamsulosin, Extracorporeal Shock Wave Lithotripsy","completionDate":"2023-12-01"},{"nctId":"NCT01534351","phase":"Phase 3","title":"A Phase III, Randomized Clinical Trial to Study the Safety and Efficacy of MK-906 (Finasteride) and Tamsulosin Administered Either Alone or Concomitantly in Patients With Benign Prostatic Hyperplasia ","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":1,"indication":"Benign Prostatic Hyperplasia","completionDate":"2013-11-18"},{"nctId":"NCT06001619","phase":"Phase 4","title":"Prostate Medication, Metabolism and Gut Microbiota","status":"RECRUITING","sponsor":"Turku University Hospital","isPivotal":false,"enrollment":100,"indication":"Prostatic Hyperplasia, Prostate Cancer","completionDate":"2026-12-31"},{"nctId":"NCT04987892","phase":"Phase 4","title":"Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for Benign Prostatic Hyperplasia","status":"UNKNOWN","sponsor":"NeoTract, Inc.","isPivotal":false,"enrollment":250,"indication":"BPH","completionDate":"2025-10"},{"nctId":"NCT01076309","phase":"N/A","title":"Corneal Endothelium Cell Loss After Cataract Extraction in Patients Taking Systemic Sympathetic Alfa-1-a-antagonist Medication (Tamsulosin)","status":"COMPLETED","sponsor":"Frederiksberg University Hospital","isPivotal":false,"enrollment":60,"indication":"Cataract","completionDate":"2010-09"},{"nctId":"NCT05494567","phase":"Phase 4","title":"Efficacy of Tadalafil and Solifenacin Versus Tamsulosin and Solifenacin Combination Therapy for the Treatment of Benign Prostatic Hyperplasia With Overactive Bladder: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Mansoura University","isPivotal":false,"enrollment":60,"indication":"Benign Prostatic Hyperplasia, Overactive Bladder","completionDate":"2022-08"},{"nctId":"NCT02034604","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Samsung Medical Center","isPivotal":false,"enrollment":194,"indication":"Neurogenic Lower Urinary Tract Dysfunction","completionDate":"2017-08"},{"nctId":"NCT02247505","phase":"Phase 1","title":"A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Pharmacokinetic Effect of Tadalafil on Tamsulosin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","isPivotal":false,"enrollment":29,"indication":"Healty Male Volunteers","completionDate":"2014-12"},{"nctId":"NCT05977647","phase":"Phase 4","title":"Comparison of Silodosin Versus Tamsulosin on Passage of Acutely Obstructing Ureteral Calculi (History of Last 4 Weeks) in Medical Expulsive Therapy","status":"COMPLETED","sponsor":"Getz Pharma","isPivotal":false,"enrollment":240,"indication":"Ureteric Stone of Lower Third of Ureter","completionDate":"2025-06-30"},{"nctId":"NCT02184585","phase":"Phase 1","title":"An Open-label, Randomized, Single Dose, Three-way Crossover Study to Determine the Bioavailability of Two Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5mg","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":84,"indication":"Prostatic Hyperplasia","completionDate":"2015-02-23"},{"nctId":"NCT04232683","phase":"EARLY/Phase 1","title":"Preoperative Tamsulosin to Prevent Postoperative Urinary Retention in Females After Surgery For Pelvic Floor Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","isPivotal":false,"enrollment":100,"indication":"Urinary Retention","completionDate":"2025-12"},{"nctId":"NCT01175382","phase":"Phase 2","title":"Combined Behavioral and Drug Treatment of Overactive Bladder in Men","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","isPivotal":true,"enrollment":204,"indication":"Overactive Bladder, Lower Urinary Tract Symptoms","completionDate":"2015-07"},{"nctId":"NCT02169713","phase":"Phase 1","title":"A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Tamsulosin HCl in Healthy Male Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","isPivotal":false,"enrollment":20,"indication":"Healthy Subjects, Pharmacokinetics","completionDate":"2014-08"},{"nctId":"NCT06282731","phase":"EARLY/Phase 1","title":"The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia After Medical Treatment","status":"COMPLETED","sponsor":"En Chu Kong Hospital","isPivotal":false,"enrollment":74,"indication":"Benign Prostatic Hyperplasia","completionDate":"2017-04-27"},{"nctId":"NCT02244294","phase":"Phase 2","title":"A Two Phase, Double-blinded, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic ","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":176,"indication":"Prostate Hyperplasia","completionDate":""},{"nctId":"NCT07444385","phase":"Phase 1","title":"An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Period Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Volunteers Under Fed C","status":"RECRUITING","sponsor":"Addpharma Inc.","isPivotal":false,"enrollment":44,"indication":"Benign Prostatic Hyperplasia","completionDate":"2026-05-08"},{"nctId":"NCT05570084","phase":"Phase 3","title":"Randomised Controlled Trial on Silodosin Versus Tamsulosin for Medical Expulsive Treatment of Ureteral Stones Size 5-10mm in Chinese","status":"UNKNOWN","sponsor":"Princess Margaret Hospital, Hong Kong","isPivotal":true,"enrollment":80,"indication":"Stone, Urinary","completionDate":"2023-12-31"},{"nctId":"NCT06264414","phase":"Phase 3","title":"Phase III, Multicenter, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia","status":"NOT_YET_RECRUITING","sponsor":"EMS","isPivotal":true,"enrollment":262,"indication":"Prostatic Hyperplasia, Benign, Erectile Dysfunction","completionDate":"2027-07"},{"nctId":"NCT02483793","phase":"NA","title":"Randomized Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Discomfort in the Pediatric Population","status":"WITHDRAWN","sponsor":"Phoenix Children's Hospital","isPivotal":false,"enrollment":0,"indication":"Disorder of Urinary Stent","completionDate":"2016-12"},{"nctId":"NCT07134907","phase":"Phase 4","title":"The Efficacy and Safety of Qianweitai (Silodosin Capsule) Compared to Tamsulosin in the Treatment of Benign Prostaic Hyperplasia (BPH) -A Multicenter, Prospecive, Randomized, Investigator-Blind, Posit","status":"COMPLETED","sponsor":"Shanghai Huilun Pharmaceutical Co., Ltd.","isPivotal":false,"enrollment":110,"indication":"BPH (Benign Prostatic Hyperplasia)","completionDate":"2024-07-09"},{"nctId":"NCT02869971","phase":"Phase 3","title":"Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":true,"enrollment":90,"indication":"Benign Prostatic Hyperplasia","completionDate":"2022-03-25"},{"nctId":"NCT01254071","phase":"Phase 1","title":"An Open-label, Randomized, Single Dose, Two-Period Crossover Study to Determine the Bioavailability of a Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":86,"indication":"Prostatic Hyperplasia","completionDate":"2010-12-21"},{"nctId":"NCT07447518","phase":"EARLY/Phase 1","title":"Comparison of Mirabegron ,Tamsulosin and Solifenacinin Relieving Double -J Stent Related Symptoms : Approspective Randmized Placebo Controlledtrial","status":"COMPLETED","sponsor":"Kafrelsheikh University","isPivotal":false,"enrollment":535,"indication":"Lower Urinary Tract Symptoms","completionDate":"2023-09-01"},{"nctId":"NCT02417831","phase":"Phase 1","title":"Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subj","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":34,"indication":"Prostatic Hyperplasia","completionDate":"2015-05-31"},{"nctId":"NCT01741454","phase":"Phase 4","title":"Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","isPivotal":false,"enrollment":181,"indication":"Ureteral Obstruction","completionDate":"2018-03-30"},{"nctId":"NCT02573311","phase":"Phase 3","title":"A 6-month OTC-simulated, Open Label, Uncontrolled Study of Tamsulosin 0.4 mg in Men","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"enrollment":1117,"indication":"Urological Manifestations","completionDate":"2016-08-01"},{"nctId":"NCT04434378","phase":"Phase 4","title":"The Use of Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair: A Randomized Double-Blind Placebo-Controlled Study","status":"TERMINATED","sponsor":"Jewish Hospital, Cincinnati, Ohio","isPivotal":false,"enrollment":170,"indication":"Post Operative Urinary Retention","completionDate":"2020-02-05"},{"nctId":"NCT02827578","phase":"Phase 3","title":"Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia : a Randomized, Double Bl","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","isPivotal":true,"enrollment":588,"indication":"Benign Prostate Hyperplasia","completionDate":"2017-12"},{"nctId":"NCT00831701","phase":"NA","title":"Medical Expulsive Therapy of Single Distal Ureteral Stones. A Randomised, Double-blind and Placebo-controlled Study","status":"COMPLETED","sponsor":"University of Zurich","isPivotal":false,"enrollment":100,"indication":"Ureteral Calculi","completionDate":"2008-11"},{"nctId":"NCT07156916","phase":"Phase 1","title":"A Prospective, Randomised, Open Label, Single Dose, Two-treatment, Two-period, Two-sequence, Crossover Bioequivalence Study of Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Tablets (Synthon Hispa","status":"RECRUITING","sponsor":"Berlin-Chemie AG Menarini Group","isPivotal":false,"enrollment":46,"indication":"Healthy Volunteer Male Subjects","completionDate":"2026-05-01"},{"nctId":"NCT02645890","phase":"Phase 1","title":"A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetic Profiles of CKD-397 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","isPivotal":false,"enrollment":36,"indication":"Benign Prostatic Hyperplasia","completionDate":"2015-12"},{"nctId":"NCT02972268","phase":"Phase 3","title":"Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":780,"indication":"Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia","completionDate":"2018-08-14"},{"nctId":"NCT02038868","phase":"Phase 2","title":"Double-Blind, Placebo-Controlled, Active-Referenced, Parallel-Group Comparative Study in Patients With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","isPivotal":false,"enrollment":320,"indication":"Benign Prostate Hyperplasia","completionDate":"2014-04-04"},{"nctId":"NCT06262048","phase":"Phase 2","title":"Prevention of Post Operative Urinary Retention After Thoracic Surgery: A Phase II Feasbility Trial","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","isPivotal":false,"enrollment":60,"indication":"Urinary Retention Postoperative","completionDate":"2026-02-01"},{"nctId":"NCT01149746","phase":"Phase 1","title":"A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","isPivotal":false,"enrollment":32,"indication":"Healthy","completionDate":"2004-12"},{"nctId":"NCT04807569","phase":"NA","title":"A Prospective Randomized Trial \"The Effectiveness of Peripheral Magnetic Stimulation in Men With Lower Urinary Tract Symptoms\"","status":"UNKNOWN","sponsor":"Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation","isPivotal":false,"enrollment":68,"indication":"Bladder Hypersensitivity","completionDate":"2022-04-01"},{"nctId":"NCT00771394","phase":"Phase 4","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic H","status":"COMPLETED","sponsor":"Astellas Pharma Inc","isPivotal":false,"enrollment":638,"indication":"Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy","completionDate":"2010-01"},{"nctId":"NCT00448123","phase":"NA","title":"The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients","status":"COMPLETED","sponsor":"Robert Swor","isPivotal":false,"enrollment":127,"indication":"Kidney Stones, Ureteral Stones","completionDate":"2011-09"},{"nctId":"NCT05753670","phase":"Phase 3","title":"Effect of Preoperative Single-dose Tamsulosin on Postoperative Urinary Retention After Mid-urethral Sling Placement: a Randomized, Double-blinded, Placebo-controlled Trial","status":"COMPLETED","sponsor":"Endeavor Health","isPivotal":true,"enrollment":179,"indication":"Postoperative Retention of Urine","completionDate":"2024-06-02"},{"nctId":"NCT06491108","phase":"Phase 3","title":"Vardenafil Versus Tadalafil Versus Tamsulosin in Patients With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Prospective Randomized Study.","status":"RECRUITING","sponsor":"Tanta University","isPivotal":true,"enrollment":150,"indication":"Enlarged Prostate With Lower Urinary Tract Symptoms","completionDate":"2025-07-01"},{"nctId":"NCT00540124","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Pilot Study to Evaluate the Efficacy and Safety of Tadalafil and Tamsulosin Once-a-Day Dosing for 12 Weeks in Asian Men With Signs and ","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":151,"indication":"Benign Prostatic Hyperplasia","completionDate":"2008-06"},{"nctId":"NCT02417844","phase":"Phase 1","title":"Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subj","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":34,"indication":"Prostatic Hyperplasia","completionDate":"2015-05"},{"nctId":"NCT01937871","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing for 12 Weeks in Men With Signs and Sympto","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":true,"enrollment":909,"indication":"Benign Prostate Hyperplasia, Erectile Dysfunction","completionDate":"2015-12"},{"nctId":"NCT01777269","phase":"Phase 4","title":"A Prospective Study of Sexual Function in Sexually Active Men Treated for BPH","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":489,"indication":"Prostatic Hyperplasia","completionDate":"2016-04-05"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0566/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$21","description":"TAMSULOSIN HCL 0.4 MG CAPSULE","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-10-31T00:00:00.000Z","mah":"IMPAX LABS","brand_name_local":null,"application_number":"ANDA090377"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-11-09T00:00:00.000Z","mah":"SUN PHARM INDS LTD","brand_name_local":null,"application_number":"ANDA090931"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-06-13T00:00:00.000Z","mah":"WAYLIS THERAP","brand_name_local":null,"application_number":"NDA022460"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-06-26T00:00:00.000Z","mah":"MACLEODS PHARMS LTD","brand_name_local":null,"application_number":"ANDA204645"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-07-18T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":null,"application_number":"ANDA213300"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tamsulosin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:29:24.695823+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:29:30.797344+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:29:23.826809+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tamsulosin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:29:31.154894+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:21.709431+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:21.709473+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:29:32.660600+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Adrenergic receptor alpha-1 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:29:32.204062+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200914/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:29:31.857958+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA214730","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:21.709476+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:29:35.677201+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL1200914"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}